PosterSessionOnline

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 22nd World Congress on Gastrointestinal Cancer

1-4 July 2020 Barcelona

N. Poster

Poster title

Applicant name

Status


O-001	PanCO: Updated Results of an Open-Label, Single-Arm Pilot Study of OncoSil P-32 Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma (LAPC) With Gemcitabine Nab-Paclitaxel or FOLFIRINOX Chemotherapy	David Turner	Received

LBA-001	First-line liposomal irinotecan 5 fluorouracil/leucovorin oxaliplatin in patients with pancreatic ductal adenocarcinoma: Primary analysis from a phase 1/2 study	Amie Hedges	Received

P-001	LINC00184 promotes the stemness and chemoresistance of gastric cancer by interacting with YAP and by promoting exosomes-mediated macrophage M2 polarization	Haiyan Piao	Received

SO-001	Prognostic nomogram to predict overall survival in patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: Real-world results from the multicenter retrospective study (NAPOLEON study)	Taro Shibuki	Received

P-002	An update on the trends for hepatic cancer subtypes in the Philippines, 2003-2012: A population-based study	Jansen Cambia	Received

PD-002	Role of pretreatment SUVmax on 18F-FDG PET and clinicopathological features in the prognostic stratification of newly diagnosed intrahepatic cholangiocarcinoma	Alessandro Rizzo	Received

LBA-003	CheckMate 459: Long-Term Efficacy Outcomes With Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma	Onaisa Rizki	Received

SO-003	Maintenance olaparib in patients aged &8805; 65 years with a germline BRCA mutation and metastatic pancreatic cancer: Phase 3 POLO trial	Hedy Kindler	Received

P-003	Features of metabolic profiles of blood serum and erythrocyte membranes associated with metastasis in colorectal cancer	Margarita Kruchinina	Received

LBA-004	Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer	YU SUNAKAWA	Received

LBA-005	ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600Emutant metastatic colorectal cancer	Axel Grothey	Received

O-005	Efficacy and safety of nivolumab ipilimumab in Asian patients with advanced hepatocellular carcinoma: subanalysis of the CheckMate 040 study	Onaisa Rizki	Received

PD-005	Impact of biliary drainage for unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel: Results from the NAPOLEON study	Takuya Honda	Received

P-005	Economic Burden of HCC And The Need Of Innovative Treatments	Abdalla Abotaleb	Received

SO-006	The influence of liver function on the outcomes of phase II trial of sorafenib vs. hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma	Satoshi Kobayashi	Received

P-006	Perioperative FLOT: Tolerability, pathological response rates, and the role of adjuvant phase	ERCAN ZDEN	Received

PD-006	Gemcitabine nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a population-based, multicenter AGEO study	Sonia Zaibet	Received

O-006	The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma	Bruno Sangro	Received

LBA-007	Encorafenib Plus Cetuximab With or Without Binimetinib for BRAFV600E Metastatic Colorectal Cancer (mCRC): Relationship Between Carcinoembryonic Antigen (CEA) and Clinical Outcomes From BEACON CRC	Kristen Senn	Received

PD-007	Updated survival analysis of the Danish randomized study comparing trifluridine/tipiracil with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer	Per Pfeiffer	Received

P-007	Induction chemotherapy in locally advanced rectal cancer: Retrospective report of efficacy and safety in an Argentinean university institution, a feasibility perspective	M. Celeste Diaz	Received

SO-007	Efficacy and safety of transarterial chemoembolization (TACE) plus apatinib as compared with TACE alone for recurrent hepatocellular carcinoma: A prospective randomized controlled trial	Huiying Gu	Received

P-008	Risk factors of severe gastric dysplasia and gastric cancer in rural areas of China among individuals at high-risk: A population-based, cross-sectional study	Maomao Cao	Received

O-008	Atezolizumab bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150	Daneng Li	Received

SO-009	Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo	Donna Stefanoni	Received

P-009	A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer	Said Belhadef	Received

P-010	Epidemiological and histopathological review of colorectal cancer in Tunisia	sonia Ben Nasr	Received

PD-010	Improvement of Asia-Pacific colorectal screening score combined with fecal immunochemical testing at adjusted thresholds in colorectal cancer screening	Ming Lu	Received

P-011	Impact of preoperative and postoperative variation of CEA in predicting nonmetastatic colorectal cancer recurrence.	sonia Ben Nasr	Received

PD-011	Impact of baseline symptom burden as assessed by patient-reported outcomes on overall survival of patients with metastatic gastrointestinal cancer	Atul Batra	Received

PD-012	Clinical, pathological and molecular profiles of G3 neuroendocrine tumors and neuroendocrine carcinomas	Rodrigo Taboada	Received

P-012	A descriptive analysis of patient characteristics from Russian internet postings focused on CRC (iPatient study)	Alexandr Krotkevich	Received

P-013	Current and expected future profile changes of gastric and pancreatic cancer patients at presentation	Rasha Aboelhassan	Received

O-014	Young adults with neuroendocrine tumors present a high rate of pathogenic or likely pathogenic germline variants in cancer-predisposing genes	Rachel Riechelmann	Received

P-014	Dose escalated short-course radiotherapy in rectal cancers: Is this the way forward?	Deep Chakrabarti	Received

SO-015	Radiomic signature for prediction of peritoneal disseminations in gastric cancer which were not detected by routine CT examinations	Sayuri Konishi	Received

P-15	Combined Gastrectomies: Survival Outcomes in Patients with Local Advanced Gastric Cancer	Oleg Kshivets	Received

P-017	Peri-operative FLOT: West of Scotland regional experience	Katharine Welsh	Received

SO-018	Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): Main results of the AXOAXI-trial	Pia Osterlund	Received

P-018	REMARRY and PURSUIT trials: Liquid biopsy-guided re-challenge of anti-EGFR monoclonal antibody for patients with RAS/BRAF V600E wild-type metastatic colorectal cancer	Hiromichi Nakajima	Received

O-018	Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study	Carlotta Antoniotti	Received

O-019	Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors	Pia Osterlund	Received

P-019	Role of percutaneous radiofrequency ablation in unresectable, non-metastatic intrahepatic cholangiocarcinoma: A single-institution experience	Alessandro Rizzo	Received

SO-020	Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study	BEATRICE BORELLI	Received

P-020	Identification of predictive biomarkers in colorectal adenocarcinoma	Lyudmila Akhmaltdinova	Received

P-021	Stereotactic body radiation therapy for locally advanced pancreatic cancer	Maria Veronica Vera Merino	Received

SO-021	Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)	Kristen Senn	Received

O-021	METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites	Yoshinori Kagawa	Received

SO-022	Atypical non-V600E BRAF (aBRAF) mutations as a prognostic and predictive factor in real-life metastatic colorectal cancer patients from the Nordic countries	Emerik Osterlund	Received

P-022	Efficacy of sorafenib in treatment of advanced hepatocellular carcinoma in the Mexican population: Evidence from a third level hospital in Mexico	abdel dip	Received

P-023	Microwave ablation versus radiofrequency ablation in BCLC-A hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials	Alessandro Rizzo	Received

SO-024	AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial	John Strickler	Received

P-024	Neutrophil and lymphocyte ratio as a prognostic biomarker in pancreatic cancer	Francine Luiz	Received

P-025	Single-institution experience of total neoadjuvant therapy for locally advanced rectal cancer: Long-term results	Roberto Milazzotto	Received

SO-025	A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer: BRAVERY study (EPOC1701)	Toshiki Masuishi	Received

P-026	RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma	Markus Moehler	Received

P-027	Retrospective observational analysis of p53 mutational status as a prognostic factor in TAS-102 treated metastatic colorectal cancer patients	Riccardo Giampieri	Received

P-028	Impact of p-mTOR expression on molecular-guided therapy strategies in therapy-refractory metastatic pancreatic ductal adenocarcinoma	Hossein Taghizadeh	Received

P-029	Molecular profiling of neuroendocrine tumors	Alina Isiangulova	Received

P-030	Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer	Mahmoud Elshenawy	Received

SO-031	Centralization of care leads to optimal ion and outcomes for patients with peritoneal metastases of colorectal cancer: The Catalonian regional program experience	Maria Isabel Ramos	Received

P-033	Regorafenib and trifluridine/tipiracil efficacy and safety in chemorefractory metastatic colorectal cancer patients: A single Bulgarian centre retrospective study	Nikolay Conev	Received

SO-033	Clonal ion of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line therapy	Alexander Baraniskin	Received

P-034	The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy	Markus Moehler	Received

P-035	Prognostic value of ALBI score in patients with hepatocellular carcinoma Child-Pugh A	Ana Raquel Monteiro	Received

P-036	Prognostic value of tumor laterality and recurrence risk in patients with stage III colon cancer treated with adjuvant chemotherapy	Ana Raquel Monteiro	Received

P-037	Phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study	MASAHITO KOTAKA	Received

SO-037	Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stability and microsatellite instability-high, locally advanced rectal cancer (EPOC 1504)	SATOSHI YUKI	Received

P-038	KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma	Josep Tabernero	Received

P-039	Prognostic impact of the number of administrations of oxaliplatin in the adjuvant treatment of stage III colon cancer	Joana Reis	Received

P-040	A correlation between BCL-2 modifying factor, p53 and livin gene expressions in cancer colon patients	Enas Elkhouly	Received

P-041	Understanding the clinical profiles that influence the concordance of RAS mutations between blood and tissue to guide therapy in metastatic colorectal cancer	Elena Brozos-Vázquez	Received

P-042	Primary malignant melanoma of anorectal region: An institutional experience in AIIMS Patna	JAGJIT PANDEY	Received

P-043	Ramucirumab effectiveness in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma in clinical practice in Spain: Sub-analysis of RAMIS study	Maria Ortega	Received

P-044	Transcatheter arterial chemoembolization using CDDP without Lipiodol for super-elderly patients with hepatocellular carcinoma	Takeshi Aramaki	Received

P-045	Applicable value of transanal endoscopic microsurgery for high-risk rectal adenoma and early rectal cancer: Experience from 126 cases	Yunhao Li	Received

P-046	Advanced colorectal adenoma detection based on altered methylation signal in plasma samples	Kristi Kruusmaa	Received

P-047	A phase I/II study of pembrolizumab in combination with ibrutinib for advanced, refractory microsatellite stable colorectal cancers	Elaine Tan	Received

P-048	First evidence for the antitumor activity of nanoliposomal irinotecan in metastatic biliary tract cancer	Hossein Taghizadeh	Received

P-049	A study of first-line treatments for patients with BRAFV600E mutant metastatic colorectal cancer in a real-life setting: CAPSTAN study	Erika Martinelli	Received

P-050	Safety and tolerability of regorafenib: A real-life experience	Youssif Abo Elseud	Received

P-051	Immunoscore in rectal cancer patients receiving radiation followed by mFOLFOX with avelumab	Ali Shamseddine	Received

P-052	The diagnostic dilemma between chronic pancreatitis and pancreatic cancer	Turon Mirzaev	Received

P-053	Clinical evaluation of complex treatment of colorectal cancer with liver metastases	Marufjon Salokhiddinov	Received

P-054	BISQUIT: A randomized phase II study of the administration of prebiotics and probiotics during definitive treatment with chemotherapy-radiotherapy for patients with squamous cell carcinoma of the anal canal	Rachel Riechelmann	Received

P-055	GASTHER2: Efficacy of adding trastuzumab to standard chemotherapy in patients with advanced HER2-negative gastric cancer and HER2-positive expression in circulating tumor cells	Rachel Riechelmann	Received

P-056	Importance determination of interleukin-6 in bile and blood in tumours of the bileopancreatoduodenal zone	Marufjon Salokhiddinov	Received

P-058	Survival and prognostic factors in metastatic gastric cancer: results from a Bangladeshi cohort	Md Shuayb	Received

P-059	High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer	Ryoichi Sawada	Received

P-061	nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Real life	Esther Una Cidon	Received

P-062	Inferior survival for mismatch repair deficient metastatic colorectal cancer observed in an Irish cohort	Alice Talbot	Received

P-063	FOLFIRINOX in borderline resectable pancreatic carcinoma	Esther Una Cidon	Received

P-064	P-in and factor VIII as risk factors of thromboembolic disease in patients with hepatocellular carcinoma	Matej Hrncar	Received

P-065	Locally advanced/metastatic gastric cancer: Real-world data on first-line treatment with oxaliplatin and cisplatin-based doublets	Helena Luna Pais	Received

P-066	Treatment with FOLFIRI-aflibercept in an elderly population (over 75 and octogenarians) with metastatic colorectal cancer after failure of an oxaliplatin-based regimen: Experience in a real-life population	Gabriella Buccafusca	Received

P-067	Short-term outcomes of capecitabine plus oxaliplatin versus S-1 plus oxaliplatin as adjuvant chemotherapies for advance gastric cancer after laparoscopic gastrectomy and D2 resection: A prospective, multicenter randomized, controlled clinical trial	Yongjia Yan	Received

P-069	Efficacy and safety of S-1 following gemcitabine plus cisplatin for biliary tract cancer	Hiroto Inoue	Received

P-070	Multimodal treatment in metastatic colorectal cancer improves outcomes: a University College London Hospital experience	Nalinie Joharatnam-Hogan	Received

P-071	Prognostic biomarkers of therapy by hepatic radioembolization with Ytrio-90 spheres in colorectal liver metastases	Eva M Triviño-Ibáñez	Received

P-072	Biomarkers of survival and therapeutic response to hepatic radioembolization with Ytrio-90 spheres in hepatocellular carcinoma	Eva M Triviño-Ibáñez	Received

P-073	Clinical prognostic factors for overall survival and time to progression in RAS-wild type metastatic colorectal cancer treated with anti-EGFR monoclonal antibodies as third or subsequent-line therapy	Tomasz Lewandowski	Received

P-075	Retrospective comparison between FLOT perioperative chemotherapy vs surgery followed by adjuvant chemotherapy: Results from a multicenter analysis	Maria Giuditta Baleani	Received

P-076	A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer	Samantha Nguyen	Received

P-077	Real-world evidence on second-line treatment of fluoropyrimidine, irinotecan, and anti-VEGF antibody for metastatic colorectal cancer	Takeharu Yamanaka	Received

P-078	Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies	Emma McConnell	Received

P-079	C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens	Marianna Luciana Ferrara	Received

P-080	TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma	Pascal Hammel	Received

P-081	Phase I-II of the update of the EORTC quality of life gastric module QLQ-STO22	Mitsumi Terada	Received

P-082	Clinical features of Japanese patients with detailed RAS/BRAF mutant colorectal cancer	Hironaga Satake	Received

P-083	Pancreatic cancer, treatment options, and sequential therapy: The experience of a district oncology center	Alícia Oliveira	Received

P-084	Colon cancer in the elderly: A comprehensive assessment of treatment and its outcomes	Alícia Oliveira	Received

P-086	Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial	Feng Bi	Received

P-088	A multicenter analysis of the correlation between overall survival and progression-free survival and the number of chemotherapeutic key drugs used in patients with advanced/unresectable pancreatic cancer: Results from the NAPOLEON study	Tsuyoshi Shirakawa	Received

P-089	Validation of the prognostic significance of the dNLR (2.2) in a population-based cohort of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy	Juan Ruiz Bañobre	Received

P-090	Does the postoperative course of events influence 2-year mortality in patients undergoing hyperthermic intraperitoneal chemotherapy? An evaluation by a novel scoring system	Mrudula Tatakuri	Received

P-091	A retrospective analysis of maintenance strategies in metastatic gastric and gastroesophageal cancer	Daniel Walden	Received

P-092	Autophagy drugs are dynamic regulators of long non-coding RNA expression in colorectal cancer	Md Zahirul Islam Khan	Received

P-093	Levels of steroid hormones, their precursors and ACTH in the blood of patients with pancreatic diseases	Olesia Ossovskaya	Received

P-094	Predictive assessment of peritoneal spread in patients with gastric cancer	Elena Frantsiyants	Received

P-095	Non-metastatic anal cancer outcomes: A single-center experience	Diana Simão	Received

P-096	Levels of sex hormones and sex steroid receptors in pathological tissues in gastric cancer patients	Olesia Ossovskaya	Received

P-097	Functions of antioxidant enzymes in the blood of patients with pancreatic neuroendocrine tumors	Olesia Ossovskaya	Received

P-098	HGCSG1902: Multicenter, prospective, observational study for cases with dysgeusia caused by chemotherapy for gastrointestinal cancer	Takayuki Ando	Received

P-099	Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: Phase 3 KEYNOTE-966 trial in progress	Arndt Vogel	Received

P-100	Quality of life assessment and reporting in gastric cancer treatment: A systematic review of phase 3 clinical trials published between 2010 and 2019	Angela Dalia Ricci	Received

P-102	The impact of a multidisciplinary approach in the management of pancreatic disease	BRUNELLA DI STEFANO	Received

P-103	The role of primary tumor site as a prognostic factor after resection of colorectal liver metastases: A mono-institutional cohort study.	Floriana Camarda	Received

P-105	Defining novel regulators of inflammatory signaling in pancreatic cancer	Jane Parry	Received

P-106	Liver metastasis in colorectal cancer: Management and survival outcomes of liver metastasectomy in a single-center analysis	Marta Vilaa	Received

P-107	LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment	Sadahisa Ogasawara	Received

P-108	Perioperative chemotherapy in locally advanced, resectable gastric cancer: A single-center experience	Marta Vilaa	Received

P-109	Global mortality for biliary tract cancer	Huifen Wang	Received

P-111	Prognostic value of inflammation-based scores for patients treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel	Shintaro Nakano	Received

P-112	HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibody	Hiroshi Nakatsumi	Received

P-113	Supportive medication in advanced biliary tract cancers with ABC-02 regimen	joni howells	Received

P-114	Cytokines as a prognostic marker of overall survival in pancreatic cancer: A meta-analysis and systematic review	Harold Nathan Tan	Received

P-115	PEMREC: A phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized microsatellite stable rectal cancer	Thibaud Kssler	Received

P-116	Impact of the number of harvested lymph nodes on survival in Egyptian patients with gastric cancer: Middle eastern tertiary center experience	Hussein Fakhry	Received

P-117	Prognostic role of plasmatic exosomal and tissue caveolin-1 in metastatic pancreatic cancer patients	Alessandro Bittoni	Received

P-118	Gastroenteropancreatic neuroendocrine tumors: Experience of the oncology department of the Oran military hospital	Amir Zakaria DJOUNIDI	Received

P-119	Special mouthwash and chronology of oral mucositis in previous cycle to prevent future episodes	Esther Una Cidon	Received

P-120	Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY Study in CIRCULATE-Japan (trial in progress)	Hiroki Yukami	Received

P-122	Treatment related response of T regulatory cells and cytotoxic lymphocytes in early PDAC	Skaiste Tulyte	Received

P-123	Outcomes and predictive factors of regorafenib benefit in patients with metastatic colorectal cancer in a real-life setting.	Nieves Martinez Lago	Received

P-124	Tumor budding and CDX2 as additional prognostic factors in stage II colon cancer	Debora Ierinò	Received

P-125	Radiomic prediction model for pathological responses of neoadjuvant chemotherapy with S-1 plus oxaliplatin (G-SOX) in clinical stage III gastric cancer	Dai Manaka	Received

P-126	Markers of tumour inflammation are prognostic for overall survival in patients with advanced pancreatic ductal adenocarcinoma receiving FOLFIRINOX chemotherapy	KONSTANTINOS KAMPOSIORAS	Received

P-127	Potential mechanism of circRNA 000585 in cholangiocarcinoma	Fengming Yi	Received

P-128	A novel combination of GEMOX and apatinib in treatment of unresectable or metastatic cholangiocellular carcinoma	Fengming Yi	Received

P-129	Camrelizumab combined with sorafenib versus sorafenib alone in patients with advanced hepatocellular carcinoma: A retrospective study	Qinqin Liu	Received

P-130	Short course pelvic radiotherapy for localized and oligometastatic rectal adenocarcinoma: The Mayo Clinic experience	Shing Fung Lee	Received

P-131	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial	Haeseong Park	Received

P-132	Malignant transformation of choledochal cysts: Description of a North African series of 7 cases	Anisse Tidjane	Received

P-133	Extramural venous invasion detected with an elastin stain is a powerful predictor of cancer-specific mortality in STAGE I-IIIB resected colorectal cancer	David Cyr	Received

P-134	Total neoadjuvant therapy in locally advanced rectal cancer patients: A tertiary medical center experience	Ali Shamseddine	Received

P-136	Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): Early diagnosis and treatment availability	Teodora Kolarova	Received

P-137	High rectal cancer: Whats the best treatment?	Maria Neves	Received

P-138	A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases	Shelize Khakoo	Received

P-140	Targeted NGS panel of epigenetic regulators genes: Application results for gastric cancer patients	Alexey Kalinkin	Received

P-141	The contribution of white blood cell gene expression in the prediction of gastrointestinal cancer	Panagiotis Apostolou	Received

P-142	Early gastric cancer: Identification of molecular markers able to distinguish penetrating lesions with different prognosis	Chiara Molinari	Received

P-143	Lack of expression of CDX2: Prognostic biomarker in stage IV colorectal cancer	Adriana Soares	Received

P-144	Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: Phase 3 PROOF trial	Lee Miller	Received

P-145	CT-based texture analysis using radiomics for hepatic sinusoidal obstruction syndrome (HSOS) in colorectal cancer patients treated with oxaliplatin containing chemotherapy	Kiyotaka Kawaguchi	Received

P-146	A genetic custom-made in vivo drug screening platform for colorectal cancer patients	Nahuel Villegas	Received

P-147	Efficacy and safety data of trifluridine/tipiracil treatment in advanced colorectal cancer based on the experience of Juan Ramón Jiménez Hospital in Huelva	María Amor Urbano	Received

P-150	Khorana and PROTECHT scores in predicting the risk of venous thromboembolism in pancreatic cancer: Which performed better?	Sara Dmaso	Received

P-151	The impact of adjuvant chemotherapy regimens in stage II colon cancer (CC) patients	Soraia Lobo-Martins	Received

P-152	The impact of 2nd-line treatment after 1st-line gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients	Maria Bensi	Received

P-153	Novel ultrasonographic scoring system of sinusoidal obstruction syndrome associated with oxaliplatin-based chemotherapy in patients with gastrointestinal cancer	Rika Saito	Received

P-154	Actionable targets by tumor genomic profiling in patients with cholangiocarcinoma	Lee Miller	Received

P-155	Efficacy of somatostatin analogues in the treatment of metastatic and unresectable pancreatic neuroendocrine tumors	Rafael Correa	Received

P-156	A phase Ib\II study of cetuximab and pembrolizumab in metastatic colorectal cancer	Christos Fountzilas	Received

P-157	Incidence and survival of intestinal soft tissue sarcoma: A retrospective analysis from SEER	Shuai Wang	Received

P-158	Clinical impact of oral intake in third-line treatment for advanced gastric cancer	TAKATSUGU OGATA	Received

P-160	A phase II study of resection followed capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Safety analysis	Takanori Watanabe	Received

P-161	Efficacy of third-line anti-EGFR-based treatment versus regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients	raffaella vivolo	Received

P-162	Perioperative capecitabine-oxaliplatin chemotherapy in resectable gastric cancer	arezki arab	Received

P-163	Systemic chemotherapy for previously treated metastatic small bowel ddenocarcinoma	Taiko Nakazawa	Received

P-164	The role of response as a predictor of improved outcome in advanced pancreatic cancer patients treated with first-line gemcitabine plus nab-paclitaxel	marta chiaravalli	Received

P-166	Baseline radiomics features in metastatic colorectal cancer: Correlation with metastatic site and clinical-pathological characteristics	Annunziato Anghelone	Received

P-167	Impact of testosterone on sexual function in women with rectal cancer: A prospective, longitudinal, cohort study	Annika Svanstrm Rjvall	Received

P-169	A first-in-human Phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers	James J. Harding	Received

P-170	Understanding patient experience in hepatocellular carcinoma (liver cancer): A qualitative patient interview study	Shethah Morgan	Received

P-171	Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet REFLECT trial inclusion criteria	Takuya Sho	Received

P-172	Prognostic factors in metastatic gastric cancer patients	Élia Cipriano	Received

P-173	The role of maintenance therapy in the first and second lines of treatment of metastatic colorectal cancer	Danila Gridnev	Received

P-175	Total neoadjuvant treatment versus standard therapy (neoadjuvant radiochemotherapy and adjuvant chemotherapy) of rectal cancer with high-risk factors for local or systemic recurrence	Vaneja Velenik	Received

P-176	Epidemiology and clinical outcomes of patients with pancreatic tumors discussed in tumor board	Juliana Silva	Received

P-177	Overall survival of patients with left-sided metastatic colorectal cancer in real life: Experience from University Hospital for Tumors in Zagreb, Croatia	Mirjana Pavlovic	Received

P-178	Prognostic impact of immune-related adverse events with nivolumab or pembrolizumab monotherapy in patients with advanced gastric cancer: A multicenter retrospective analysis	iori motoo	Received

P-179	The screening and consensus based on practices and evidence (SCOPE) survey: Results of a real-world survey on metastatic colorectal cancer practice patterns	Joanne Franklin	Received

P-181	Role of detection and quantification of plasma ctDNA RAS mutations by BEAMing digital PCR in patients with locally advanced and metastatic pancreatic cancer	Stefania Gkoura	Received

P-182	Understanding biliary tumours: Survival outcomes and prognostic factors in a single center	Diogo Silva	Received

P-183	Inflammatory Response Prediction of Systemic Therapy Outcome in Metastatic Colorectal Cancer	Amer Radwi	Received

P-184	A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma	Eric Van Cutsem	Received

P-185	Dietary factors in gastrointestinal cancers: A hospital-based case-control study	tasneef zargar	Received

P-186	Introduction of DYPD screening and its impact on treatment decisions: One centres experience	Alexander Burnett	Received

P-187	Impact on survival of local complications in pancreatic cancer: Experience at the Ramón y Cajal University Hospital (HURyC)	María San Román Gil	Received

P-188	Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients	Irene Pecora	Received

P-189	Role of radiomics in clinical prognostication and prediction of survival among a cohort of metastatic intrahepatic cholangiocarcinoma	Venkata pradeep babu koyyala	Received

P-190	A retrospective study of regorafenib versus trifluridine/tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: Multi-institution real-life clinical data	Pasquale Vitale	Received

P-191	Optimal age to start screening for colorectal cancer in average-risk adults: 50 or 45 years old?	Dimitrios Tzilves	Received

P-192	ART SCORE in determining the feasibility of TACE in hepatocarcinoma	Filipa Macedo	Received

P-193	Safety, tolerability, and efficacy of total neoadjuvant therapy for adult patients with locally advanced high-risk rectal adenocarcinoma: Retrospective real-world data from South India	Ajoy John	Received

P-194	The use of cytoreduction and HIPEC in the treatment of peritoneal carcinomatosis: The experience in Ramón y Cajal University Hospital	Jorge Esteban Villarrubia	Received

P-195	Treatment outcomes of trifluridine/tipiracil therapy in refractory metastatic colorectal cancer: A single-centre observational study	Juraj Prejac	Received

P-196	CA 19-9 and CEA as markers of survival in rectal cancer	Fatima Aurora Aires	Received

P-198	The AST/ALT ratio predicts clinical outcome in pancreatic cancer patients treated with capecitabine and gemcitabine: a single institution experience in the west of Algeria	aicha bengueddach	Received

P-199	The prognostic and therapeutic impact of microsatellite instability in stage II colon cancer: Medical oncology service chu hassan II fes	SOUMIA BERRAD	Received

P-200	Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution	Emilio Francesco Giunta	Received

P-201	Neoadjuvant hypofractionated intensity-modulated radiotherapy with a simultaneous integrated boost combined with capecitabine in locally advanced rectal cancer	Maria Veronica Vera Merino	Received

P-202	Demographics and Clinical Characteristics of Metastatic Colorectal Cancer Patients Treated With a Biosimilar to Bevacizumab	Whitney Rhodes	Received

P-203	Restaging rectal cancer after neoadjuvant chemoradiation therapy: Is magnetic resonance imaging accurate enough?	Rita Félix Soares	Received

P-204	C60 fullerene inhibits hepatocellular carcinoma development and metastasis: in vitro and in vivo studies	Halyna Kuznietsova	Received

P-205	Could chemotherapy still be useful in Hepatocarcinoma? Experience at a single institution in Lima-Perú	Cristian Pacheco-Román	Received

P-206	Prognosis of Patients Presenting as Carcinoma of Unknown Primary and Effectiveness of Acute Oncology Service: A Single Institution Experience	Rajarshi Roy	Received

P-208	Is there a role for adjuvant chemotherapy in ypN0 disease rectal cancer patients?	Rita Félix Soares	Received

P-209	Multicenter Real Life Experience of Biological Agents in patients with Metastatic Colorectal Cancer	Duygu Cevik	Received

P-210	The outcomes and toxicity of FOLFIRINOX treatment in a cohort of patients with incurable pancreatic cancer treated in a single centre in Northern Ireland.	Olivia Devlin	Received

P-211	Prognostic value of interleukin-6 in colon cancer patients: a prospective study in 60 Tunisian patients	Ichrak Ben Abdallah	Received

P-212	Factors affecting median PFS in patients with advance, non-resectable well differentiated pancreatic neuroendocrine tumors treated initially with Octreotide LAR - real world data. .	Agnieszka Kolasi&324;ska-&262;wikla	Received

P-213	Role of reactive oxygen species, IL-6 and KRAS mutation in rectal adenocarcinoma	Luiza Serbanescu	Received

P-214	A single-centre experience of adjuvant oxaliplatin based chemotherapy in elderly stage II-III colorectal cancer patients	Hannah Reed	Received

P-215	Phase 2 HEPANOVA study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC): Interim safety analysis	Chelsea Higgins	Received

P-216	Incidence and trends of biliary tract cancer in Girona: A population-based study from the Girona Cancer Registry (1994-2016)	Adelaida García Velasco	Received

P-217	Value of liquid biopsy using high-affinity plasma DNA binding magnetic beads and qualitative real-time PCR for KRAS, NRAS and BRAF mutations in metastatic colorectal cancer patients	Jessica Lucchetti	Received

P-219	Clear cell variant of hepatocellular carcinoma (HCC-CC): a single-center observational study of an uncommon subtype	Francesca Salani	Received

P-220	Management of colorectal cancers: improving clinical management of patients with MSI-high disease through education	KINJAL PARIKH	Received

P-221	Clinical and pathological characteristics of patients with gastrointestinal neuroendocrine tumors in the United States	Dina El-Habashy	Received

P-222	Primary malignant tumors of the small intestine: Clinical and therapeutic aspects	SOUMIA BERRAD	Received

P-223	Prognostic role of inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy	George Papaxoinis	Received

P-224	Improving the management of patients with pancreatic cancer: Education from treatment to adverse events and coordination of care	KINJAL PARIKH	Received

P-225	KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy	Tatiana Cunha Pereira	Received

P-226	Analysis of Hispanic Latino American Patients with Colorectal Cancer, Clinical Features and Laterality as a Prognosis Factor of Overal Survival	Calderillo-Ruiz German	Received

P-227	Prognostic and predictive factors of platinum-based chemotherapy in gastroenteropancreatic neuroendocrine neoplasms G3	Agnieszka Kolasi&324;ska-&262;wikla	Received

P-228	SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for aerodigestive tract malignancies	William Losin	Received

P-229	Elderly population do benefit from adjuvant chemotherapy in gastric cancer: Experience in a single institution	Cristian Pacheco-Román	Received

P-232	Clinical Outcomes and Characteristics According to Localization of Colorectal Cancer In Fundacion Santa Fe De Bogota Between May 2015- May 2019	Luis Pino	Received

P-233	Metformin combined with irinotecan in patients with refractory colorectal cancer: A phase 2 trial	Raphael L. Araujo	Received

P-234	A SEER based analysis of clinical characteristics and survival in patients with functional endocrine tumors of gastrointestinal origin	Apoorva Jayarangaiah	Received

P-235	Management of constipation associated with advanced cancers, chemotherapy and opioid-induced constipation by oral herbal supplement in heterogeneous group of gastrointestinal, hepatobiliary and pancreatic cancers	Anandrao Patil	Received

P-236	New polyclonal antibody therapeutic to treat esophageal adenocarcinoma and Barretts esophagus by targeting EPHB4	Pablo GarciaValtanen	Received

P-237	Impact of adjuvant chemotherapy in poorly cohesive gastric carcinoma: Experience from the Peruvian National Cancer Institute	Mariana Serrano	Received

P-239	Patient-reported outcomes in patients with metastatic gastric and esophageal cancers near end-of-life	Atul Batra	Received

P-240	Anal cancer treatment: Major reduction of acute toxicity with an approach using 4-fractions-per-week	Cam Nguyen	Received

P-241	First- and Second-Line treatment With Tyrosine Kinase Inhibitors After Chemoembolization In Intermediate-Stage Hepatocellular Carcinoma Patients	Dimitrios Dimitroulopoulos	Received

P-242	Germline mutations identified in Colombian patients with Lynch syndrome	John Jairo Suarez Olaya	Received

P-243	Incidence and survival of pancreatic neuroendocrine tumours in Girona, Spain	Raquel Guardeño Sánchez	Received

P-244	Demographic Data, Risk Factors, and Clinical Aspects of Hepatocellular Carcinoma (HCC) in Southeastern Europe During the Last Decade	Dimitrios Dimitroulopoulos	Received

P-245	GETNET-SILVELUL Study: An original or modified Immunohistochemical Score (IPS or mIPS) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with Everolimus or CAPTEM	Antonio Viudez	Received

P-246	Taxane cross-resistance: An exploratory analysis of second-line chemotherapy for metastatic gastric cancer	Paola Di Nardo	Received

P-247	Real-world clinical outcomes for third-line standard of care regimens in deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer in France.	Romain Cohen	Received

P-248	Quality of life among Tunisian gastrointestinal cancer patients undergoing chemotherapy	Ennouri Sana	Received

P-249	Resecting the unresectable: Superior survival of triple modality pancreatic adenocarcinoma patients	Yang Jian Ong	Received

P-250	Significance of microsatellite instability PCR evaluation for metastatic colorectal cancer patients: Dynamic changes during disease course (preliminary results)	Petrova Veneta	Received

P-251	Diversity of Helicobacter pylori genotypes in tumoral, adjacent and antral tissue of Colombian patients with gastric cancer	Alix Guevara	Received

P-252	Serial cytokines as potential predictive/prognosis biomarkers in potentially resectable pancreatic adenocarcinoma	Iranzu Gonzalez	Received

P-254	An experience of two Croatian centers in the treatment of gastroenteropancreatic neuroendocrine neoplasms with long-acting octreotide treatment	Borislav Belev	Received

P-255	Effects of tumor treating fields (150 kHz) in combination with FOLFOX on gastric cancer cells in vitro	Adi Haber	Received

P-256	Survival rates of locally advanced and metastatic pancreatic cancer in Western Australia	Yang Jian Ong	Received

P-257	Deep Polychromatic Flow Cytometry Characterization of Circulating Endothelial Cells in Metastatic Colorectal Cancer Patients	Davide Brocco	Received

P-258	Evaluation of volumetric modulated arc therapy with simultaneous integrated boost in carcinoma of the anal canal	Mariacarla Valli	Received

P-259	Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis	Sik Kwan Chan	Received

P-260	Nave indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine nab-paclitaxel or FOLFIRINOX chemotherapy versus standard-of-care treatment in unresectable locally advanced pancreatic cancer	David Turner	Received

P-261	Safety and effectiveness of tumor treating fields combined with sorafenib in preclinical models of hepatocellular carcinoma	Adi Haber	Received

P-262	Effect of neoadjuvant chemotherapy in patients with gastric cancer: A retrospective study	behourah zoubida	Received

P-263	The role of biologic targets in metastatic colorectal cancer in non-elderly patients: A single institutional analysis	Marta Peixoto	Received

P-264	Clinical validation of next-generation sequencing as a liquid biopsy for the monitoring of patients with metastatic colorectal cancer	Myrto Kastrisiou	Received

P-265	The study of mutations of the KRAS, NRAS, and BRAF genes in patients with colorectal cancer depending on gender, age, race in the population of the Republic of Kazakhstan	Yelena Ukolova	Received

P-266	LDH levels as predictors of efficacy in second-line treatment for metastatic gastric cancer: the LINE study	Anna Michelotti	Received

P-267	Signet-Ring Cell Carcinoma of the Colon: 10-Case Experience of the Medical Oncology Department at Hassan II University Hospital	SOUMIA BERRAD	Received

P-268	Diabetes and risk of pancreatic cancer	Alaeddine SAIDI	Received

P-269	Lenvatinib in hepatocellular carcinoma: QoL surveys and radiological imaging markers predicting clinical outcome in patients with hepatocellular carcinoma treated with lenvatinib as first-line treatment (SULENVA-HCC)	Nicoletta Zanaletti	Received

P-270	Early tumor shrinkage as a predictor of favorable outcomes in patients with unresectable metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab	behourah zoubida	Received

P-271	Meta-analyses on mutation status concordance between tumor tissue and circulating tumor DNA (ctDNA) and prognostic value of ctDNA in pancreatic cancer (PC)	Anna Popova	Received

P-272	Sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy	Chiara Maddalena	Received

P-273	Real-world experience of definitive chemoradiation in esophageal cancer: Correlation of tumour length, toxicity and disease control	Rajarshi Roy	Received

P-274	RELEVANT study: Patient and physician perspectives on clinically-meaningful outcomes in advanced pancreatic ductal adenocarcinoma	Rille Pihlak	Received

P-275	Quality of life and symptoms in patients undergoing CRS-HIPEC with or without perioperative systemic treatment for colorectal peritoneal metastases: results from the randomised CAIRO6 trial	Checca Bakkers	Received

P-276	Neutrophil/lymphocyte ratio (NLR) predicts survival after curative treatments for rectal cancer patients	Edna Darlene Rodrigues Pinto	Received

P-277	Epidemiology of pancreatic cancer: Experience of the medical oncology department of CHU HASSAN II fez	hayat Erraichi	Received

P-278	Neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios as predictive markers of pathological response to FLOT neoadjuvant strategy in locally advanced gastric/gastroesophageal junction cancer	Tiago Cruz Tomás	Received

P-279	Clinical utility of circulating tumor DNA (ctDNA) in resectable and advanced pancreatic cancer (PC)	Anna Popova	Received

P-280	The comparison of mFOLFOX-6, mDCF, mFOLFIRINOX in the first-line treatment of advanced gastric cancer	Ekaterina Ignatova	Received

P-281	Colon Cancer in Elderly Patients: Experience of the Medical Oncology Department of CHU HASSAN II Fez	hayat Erraichi	Received

P-282	Long-term outcomes after neoadjuvant chemoradiotherapy and R0 resection in ESCC : A propensity-matched analysis of PF versus CROSS regimen	Ka-On Lam	Received

P-283	Analysis of KRAS mutation allele in circulating cell-free DNA derived from urine in colorectal cancer patients	Ryo Ohta	Received

P-285	Therapeutic management of exocrine pancreatic cancer in elderly patients	Alaeddine SAIDI	Received

P-288	Nerve fibers in the tumour microenvironment are co-localized with tertiary lymphoid structures and is associated with better survival in pancreatic cancer patients	Lara Heij	Received

P-289	Role of the neoadjuvant chemoradiotherapy in esophageal cancer: Our centers experience	Tanny Barreto	Received

P-291	Retrospective comparison efficacy and toxicity FOLFIRI plus aflibercept or bevacizumab in patients with metastatic colorectal cancer: Results of the multicenter observational study	Mikhail Fedyanin	Received

P-292	Locally advanced esophageal cancer: Pattern of care, treatment outcomes and prognostic factors over a 20-year experience at the Modena Cancer Centre	Fabio Canino	Received

P-293	Overall survival according to mutation frequency of BRAF, NRAS genes, and MSI status in patients with wild-type KRAS metastatic colorectal cancer treated with cetuximab	Raphael L. Araujo	Received

P-294	Incorporating genetic counseling service into the gastrointestinal tumor board: Experience, obstacles, and opportunities in a Mexican center	Guillermo Pacheco Cuellar	Received

P-295	Patterns of failure following neoadjuvant and definitive radiation strategies in carcinoma thoracic esophagus: Do we need to rethink targets?	Farhan Ahmad	Received

P-296	Chemosensitivity and Outcome in Advanced And Metastatic Gastric Signet-Ring Cell Carcinoma (GSRC)	Priscila Nejo	Received

P-298	Surgical resection of primary tumor as a prognostic factor in stage IV colon adenocarcinoma	Kanika Nair	Received

P-299	Cytoreductive surgery with gastrectomy and HIPEC for gastric cancer with limited peritoneal metastases treated with neodjuvant systemic therapy is feasible and safe	Maria Isabel Ramos	Received

P-300	Overall survival with single vs multi-agent chemotherapy in stage IIIA colon adenocarcinoma	Kanika Nair	Received

P-301	Gastrointestinal stromal tumors: 10 years of experience in the medical oncology department at Mohammed VI university hospital in Marrakech, Morocco	mohamed kaakoua	Received

P-302	Prognostic factors in stage IV appendiceal adenocarcinoma	Kanika Nair	Received

P-303	Definitive radiation for esophageal cancer: Experience of a Portuguese cancer center	Bárbara de Castro	Received

P-304	Effectiveness and safety of thermal ablation of pulmonary metastases in patients with colorectal cancer	Nishanthi Silva	Received

P-305	Efficacy and safety of IMATINIB in gastrointestinal stromal tumors: Experience of the medical oncology department of the CHU Hassan II of FES	Nouiakh Lamyae	Received

P-307	Colorectal cancer in young people under 45: Experience of the medical oncology service of the Hospital Hassan II of FEZ	Nouiakh Lamyae	Received

P-309	Correlation between baseline CEA levels and TNM stage at presentation in colorectal cancers in an Indian population	Venkata pradeep babu koyyala	Received

P-311	Low Risk of Advanced Neoplasms for up to 20 Years after Negative Colonoscopy:Potential for Personalized Follow up Screening Intervals	Thomas Heisser	Received

P-312	Perioperative Chemotherapy Versus Surgery Alone on Resectable Advanced Gastric Cancer in a Moroccan Population	siham Lalaoui Rachidi	Received

P-313	Management of frail patients with metastatic pancreatic ductal adenocarcinoma: A single-institution experience	Andrea Plaja Salarich	Received

P-314	Supine VMAT versus prone 3D-EBRT in preoperative rectal cancer: Dosimetric comparison and pathological response with each radiotherapy technique	Laura Diaz	Received

P-315	Impact of tumor location (right vs left) as a prognostic and predictive factor in colon cancer in a Moroccan population: A single-center study	Nada Benhima	Received

P-317	Survival outcomes among patients with locally advanced esophageal cancer treated within a multidisciplinary gastro-esophageal cancer functional unit	Andrea Plaja Salarich	Received

P-318	Survival outcomes among patients with locally advanced gastric cancer treated within a multidisciplinary gastro-esophageal cancer functional unit	Angelica Ferrando Díez	Received

P-320	Genetic testing for microsatellite instability and KRAS mutation in stage IV colorectal cancer: Trends and outcomes from the National Cancer Database.	Johannes Uhlig	Received

P-321	The voice beyond the clinic: Delineation of young-onset cancer patient profiles using a digital social network	Ilit Turgeman	Received

P-322	Nutritional intervention impact on body mass index and toxicities related to 1st-line metastatic colorectal cancer treatment with targeted therapy	David da Silva Dias	Received

P-323	RAS mutations in metastatic colorectal cancer in central Tunisia	Melliti Rihab	Received

P-324	Advanced hepatocellular cancer: current systemic treatment sequencing and outcomes in the United States	Johannes Uhlig	Received

P-325	EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity	Loise Francisco-Anderson	Received

P-326	Chemoradiotherapy treatment in gastroesophageal junction tumors	Jesica Storino	Received

P-328	Biliary tract cancers: Epidemiology and trends in Tunisian patients	Ichrak Ben Abdallah	Received

P-331	Adjuvant chemotherapy for stage II colon cancer following complete resection: Experience of the Mohammed VI University Hospital Centre oncology center in Marrakech	kawtar El bouaouidi	Received

P-332	Real world data (RWD) study of BRAF mutant metastatic colorectal cancer (mCRC) patients (pts) across the Greater Manchester region prior to BEACON trial results	Rory Cairns	Received

P-334	Perioperative chemotherapy in the treatment of resectable and locally advanced gastric and junctional esophagogastric adenocarcinoma: Experience of a Portuguese central hospital	Ema Neto	Received

P-335	Self-reported prescribing practices in the setting of adjuvant treatment for colorectal cancer	Catherine Hanna	Received

P-336	Clinical outcomes of 49 consecutive patients admitted with malignant obstructive jaundice	Syed Abdullah Javaid Bukhari	Received

P-338	Advanced pancreatic adenocarcinoma in daily clinical practice: A single-center experience	Alaeddine SAIDI	Received

P-339	Real-world data (RWD) of the use of trifluridine/tipiracil hydrochloride (TFT) in patients with metastatic colorectal cancer: The Greater Manchester experience	Alia Alchawaf	Received

P-341	Capecitabine/mitomycin versus 5-fluorouracil/mitomycin in combination with simultaneous integrated boost-intensity modulated radiation therapy for anal cancer	Léa Vazquez	Received

P-342	Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) /- chemotherapy in first-line therapy of advanced/metastatic HER2 gastroesophageal junction or gastric cancer	Minori Rosales	Received

P-344	The role of postoperative prognostic nutritional index as a prognostic factor and its association to systemic inflammatory response markers in stage III colon cancer	Ins Costa	Received

P-345	Evaluation of a fully automated Idylla test system for microsatellite instability in a cohort of Spanish patients with colorectal carcinoma in a single institution	Miriam Perez García	Received

P-346	Endoscopic Profiling of Various GI Malignancies in CMOSH Medical College Hospital, Chattogram, Bangladesh	Debashis Chowdhury	Received

P-347	A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients With locoregional hepatocellular carcinoma: EMERALD-1	Bruno Sangro	Received

P-348	A multi-institutional retrospective study of stage I-IV transverse colon cancer: Diagnosis, treatment and outcome analyses	Francesca Lo Bianco	Received

P-349	Clinical significance of lymph node radio to predict prognosis in colon cancer	Gyoung Tae Noh	Received

P-350	Maintenance Trastuzumab in the setting of second line treatment in HER2 overexpressing metastatic gastric and gastroesophageal junction adenocarcinoma: a single center experience	López López Flora	Received

P-351	RNA sequencing for personalized therapy prescription in colon cancer	Elena Poddubskaya	Received

P-353	Colorectal cancer liver metastases challenges and potential opportunities: Systematic review and meta-analysis	Ereny Saad	Received

P-354	Association Between Tumor Regression with Tumor Location and Inflammatory Biomarkers in Patients with Resectable Gastric Cancer and Gastroesophageal Junction Cancer who Underwent Perioperative Chemotherapy: Multicentric Data from Peru	Rodrigo Motta	Received

P-355	Trastuzumab-based treatment of HER2-positive metastatic gastric cancer	&304;zzet Do&287;an	Received

P-356	Phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study	Kentaro Yamazaki	Received

P-357	The Frequencies and Prognostic Significance of ABO Blood and Rhesus (D) Groups in HER2-Positive Gastric Cancer	&304;zzet Do&287;an	Received

P-358	Mutational status in Ras/Raf/MAPK signaling pathway in Moroccan colorectal cancer patients	Mohammed Sqalli Houssaini	Received

P-359	Biliary tract carcinoma: Management patterns and outcome	Ryma Boujnah	Received

P-360	EGFR-inhibitors in metastatic wild-type RAS colorectal cancer: Experience of the oncology department of Mohammed VI University Hospital in Marrakech	houda jouihri	Received

P-361	High expression levels of circulating miRNA-618 and miRNA-203a-3p are associated with prolonged survival in patients with metastatic colon cancer	Maria Radanova	Received

P-362	SIBO and lactose intolerance in patients receiving chemotherapy treatment for colorectal or gastric cancer	Nora Forones	Received

P-363	Clinical - Pathological Correlation of The Presence of Microsatellite Instability in Patients Diagnosed with Locally Advanced Gastric Adenocarcinoma from Costa Rica	Alejandra Méndez	Received

P-364	Higher amount of KRAS mutations in pre-operative plasma cell-free DNA predicts shorter survival after liver metastasectomy in colorectal cancer patients	Jiri Polivka	Received

P-365	Association between baseline serum levels of miRNA-143 and hepatocyte growth factor in patients with RAS wild type metastatic colorectal cancer treated with first-line anti-EGFR therapy	Zhasmina Mihaylova	Received

P-366	Long-term quality of life in patients treated for anal cancer: Self-reported bother of symptoms	Anna Axelsson	Received

P-367	A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries	Omkara Veeranki	Received

P-368	Primary tumor location in synchronous and metachronous liver metastases: Impact on patterns of recurrence and survival after hepatic resection	Rita Balsano	Received

P-369	Quality of life of caregivers of patients with gastrointestinal cancer	Nora Forones	Received

P-372	Safe moderate dose regimens retain full survival benefits for aged patients with and without resistant gastrointestinal cancers	Robert De Jager	Received

P-373	Moderate Dose Chemotherapy Retains Efficacy and Improves Safety in Conjunction with High Dose Ascorbic Acid (HDAA)	Howard Bruckner	Received

P-384	Quality of life and systemic pharmacokinetics of repetitive electrostatic PIPAC with oxaliplatin in patients with colorectal peritoneal metastases	Robin Lurvink	Received

P-385	A phase 1/2 study of combination therapy of ivaltinostat, gemcitabine, and erlotinib in patients with unresectable, locally advanced and metastatic pancreatic adenocarcinoma	Jung Hyun Jo	Received

ESMO 22nd World Congress on Gastrointestinal Cancer

1-4 July 2020 Barcelona

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 01/07/2020 TO 01/07/2023

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access